Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JY025 in advanced hepatocellular carcinoma
CTR20242318Phase 2Active
- Sponsor
- Beijing Eastern Biotech
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JY025 in hepatocellular carcinoma (HCC), sponsored by Beijing Eastern Biotech. Started Aug 2024; status: active.
02
Drugs
JY025
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20242318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242318.